Lantheus Holdings Inc (LNTH) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Lantheus Holdings Inc   (NASDAQ: LNTH)


Lantheus Holdings Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lantheus Holdings Inc's ROI in the second quarter of 2026?
Lantheus Holdings Inc achieved a return on average invested assets (ROI) of 13.28 % in its second quarter of 2026, this is above LNTH's average return on investment of 11.95%.
Lantheus Holdings Inc s investments during the 12 months ending in the second quarter of 2026 are valued at $2 billion

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 84 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 521 to 532.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 24.72 % 18.24 % 18.97 % 21.88 % 9.36 %
Y / Y Net Income Change TTM 1.59 % 9.72 % 28.77 % -13.19 % 336.59 %
Investment (TTM) in Millions 2,455 2,013 1,894 1,930 1,836
Return On Investment (TTM) 13.28 % 14.55 % 12.51 % 9.17 % 16.3 %
LNTH's Overall Ranking # 532 # 521 # 563 # 819 # 320
Seq. Investment Change TTM 8.07 % 2.76 % 2.11 % 9.99 % 2.46 %
Seq. Net Income Change TTM -1.34 % 19.47 % 39.29 % -38.13 % 6.56 %
Net Income (TTM) in Millions 275 279 234 168 271




Return On Investment LNTH's Ranking
Within: No.
Industry # 2
Sector # 85
Overall # 532

Return On Investment Statistics
High Average Low
49 %
11.95 %
-9.18 %
(Dec 31 2017)   (Dec 31 2021)



  News about Lantheus Holdings Inc Return on Investment ROI

Lantheus Celebrates CMS Rule Enhancement for Diagnostic Radiopharmaceuticals Translates to Better Patient Access and Care

November 4, 2024

In a significant move for the healthcare landscape, Lantheus Holdings, Inc. has expressed its commendation for the Centers for Medicare and Medicaid Services (CMS) recent rule concerning the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The announcement, made on November 4, 2024, signals a pivotal recognition of specialized diagnostic radiopharmaceuticals, which are critical in diagnosing and managing various diseases effectively.The final rule aims to improve the payment structure for these specialized products, enabling healthcare facilities to provide better access to essential diagnostic services for patients. By refining the accuracy of payment amounts, this reform promises to enhance the financial viability of institutions utilizing these technologies, ultimately leading to improved patient outcomes. Lantheus, a leader in the field, views this adjustment as a landmark recognition of the importance of diagnostic radiopharmaceuticals, allowing clinicians to better “Find, Fight, and Follow� diseases.






Financial Statements
Lantheus Holdings Inc's II. Quarter Investments $ 2,455 Millions LNTH's Balance sheet
Lantheus Holdings Inc's II. Quarter Income $ 75 Millions Quarterly LNTH's Income Statement
LNTH's Income by Division See LNTH's Income by Division


LNTH Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 1,894 1,740 1,464 1,074 773
Y / Y Investment Growth 8.86 % 18.86 % 36.35 % 38.83 % -2.03 %
Net Income in Millions 234 312 327 28 -71
Y / Y Net Income Growth -25.25 % -4.35 % 1063.86 % - -
Annual Return On Investment 12.33 % 17.96 % 22.32 % 2.61 % -9.22 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 12.33 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LNTH's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LNTH's Competitors
Subscribers only: Roi for Lantheus Holdings Inc's Suppliers
Subscribers only: Return On Investment for LNTH's Customers

Other Ratios
LNTH's Roa LNTH's Inventory Turnover Ratio LNTH's Growth Rates LNTH's Dividend Statistics
LNTH's Profitability Ratios LNTH's Asset Turnover Ratio LNTH's Dividend Growth
LNTH's Roe LNTH's Valuation Ratios LNTH's Financial Strength Ratios LNTH's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %


Date modified: 2026-09-26T07:21:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.